Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae

Journal of Infection and Chemotherapy

Volumn 7, Issue 2, 2001, Pages 121-123

  Ikejima, H ^a   Yamamoto, H ^a   Ishida, K ^a   Terakubo, S ^a   Kaku, M ^a   Shimada, J ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Everninomicin; Mycoplasma pneumoniae; SCH27899

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; EVERNIMICIN; LEVOFLOXACIN; MINOCYCLINE; OFLOXACIN; ROXITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN;

EID: 0034943978     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560100020     Document Type: Article

References (17)

1. Long-term epidemiology of infections with Mycoplasma pneumoniae
2. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae
3. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae
4. New directions for macrolide antibiotics: Pharmacokinetics and clinical efficacy
5. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones
6. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters
7. In-vitro and in-vivo activities of a new quinolone AM-1155 against Mycoplasma pneumoniae
8. Susceptibility of Mycoplasma pneumoniae to several new quinolines, tetracycline, and erythromycin
9. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections
10. Mutations in ribosomal protein L16 conferring reduced susceptibility to everninomicin (SCH27899): Implications for mechanism of action
11. Everninomicin, a new oligosaccharide antibiotic: Its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity
12. A phylogenetic analysis of the mycoplasmas: Basis for their classification
13. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as PPLO
14. Comparison of antibiotics in the treatment of Mycoplasmal pneumonia
15. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin
16. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae
17. Construction of an EcoRI restriction map of Mycoplasma pneumoniae and localization of selected genes